Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
Authors:
- 1 October 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 12 (10) , 1460-1469
Abstract
Malignant pleural mesothelioma (MPM) is associated with asbestos exposure and is a cancer that has not been significantly affected by small molecule-based targeted therapeutics. Previously, we demonstrated the existence of functional subsets of lung cancer and head and neck squamous cell carcinoma (HNSCC) cell lines in which fibroblast growth factor receptor (FGFR) autocrine signaling functions as a nonmutated growth pathway. In a panel of pleural mesothelioma cell lines, FGFR1 and FGF2 were coexpressed in three of seven cell lines and were significantly associated with sensitivity to the FGFR-active tyrosine kinase inhibitor (TKI), ponatinib, both in vitro and in vivo using orthotopically propagated xenografts. Furthermore, RNAi-mediated silencing confirmed the requirement for FGFR1 in specific mesothelioma cells and sensitivity to the FGF ligand trap, FP-1039, validated the requirement for autocrine FGFs. None of the FGFR1-dependent mesothelioma cells exhibited increased FGFR1 gene copy number, based on a FISH assay, indicating that increased FGFR1 transcript and protein expression were not mediated by gene amplification. Elevated FGFR1 mRNA was detected in a subset of primary MPM clinical specimens and like MPM cells; none harbored increased FGFR1 gene copy number. These results indicate that autocrine signaling through FGFR1 represents a targetable therapeutic pathway in MPM and that biomarkers distinct from increased FGFR1 gene copy number such as FGFR1 mRNA would be required to identify patients with MPM bearing tumors driven by FGFR1 activity. Implications: FGFR1 is a viable therapeutic target in a subset of MPMs, but FGFR TKI-responsive tumors will need to be selected by a biomarker distinct from increased FGFR1 gene copy number, possibly FGFR1 mRNA or protein levels. Mol Cancer Res; 12(10); 1460–9. ©2014 AACR.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Prognosis and prognostic factors of patients with mesothelioma: a population-based studyBritish Journal of Cancer, 2012
- Converting Cancer Therapies into Cures: Lessons from Infectious DiseasesCell, 2012
- Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine NetworkThe American Journal of Pathology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesotheliomaEuropean Journal of Cancer, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific mannerOncogene, 2009
- Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesotheliomaBritish Journal of Cancer, 2009
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005